ABSTRACT
Introduction Disease-Modifying Anti-Rheumatic Drug (DMARD) treatment fails to achieve clinical remission in a substantial proportion of patients with rheumatoid arthritis (RA). Patient-derived synovial tissue (ST)-signatures, thought to determine this heterogeneity of treatment responses, can be studied by single-cell RNA sequencing (scRNA-seq).
Study aims The first aim was to obtain viable ST from RA patients using wrist arthroscopy. The second aim was to identify patient-specific transcriptome signatures from the ST omics data that relate to clinical course and treatment responses in RA.
Methods Radiocarpal and midcarpal synovectomy was performed using a standard set-up wrist arthroscopy. Single-cell suspensions of ST from affected wrists of two RA patients and a control subject were processed on the 10X Genomics Chromium Platform. Seurat was used for downstream analysis.
Results In two RA patients and one non-inflammatory control, ST was successfully removed during wrist arthroscopy. No surgical complications occurred. For the RA patients and control, 17,176 and 7,884 high-quality cells were analyzed, respectively. Apart from enrichment of cell compartments in RA, including those of B- and plasma cells, T cell populations, NK cells, and macrophages, we observed interpatient variability that may influence the relationship between RA synovial signature and clinical phenotype, potentially also affecting treatment response and outcome. In-depth analysis of the prevailing cell-type abundance phenotype (CTAP) in the RA patients, as described previously, provided insights into the extent to which these CTAPs may be used to predict treatment responses.
Conclusion In this feasibility study, we demonstrated that wrist arthroscopy successfully retrieves ST with good tissue viability, which may provide informative and high-quality transcriptomic data for predicting therapy response at an individual level.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical Research Ethics Committees United (Nieuwegein, Netherlands) of Maasstad hospital (Rotterdam, Netherlands) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Raw sequencing data have been deposited in the NCBI GEO repository (GSE number follows) and will be publicly available as of the date of publication. The code used for analysis is available upon request.
